Mepolizumab, a humanized monoclonal antibody that targets interleukin-5 (IL-5), significantly reduced COPD exacerbations in ...

The COPD approval marks the fifth Nucala has received from the FDA, following green lights in severe asthma, chronic ...

Current recommendations for diagnosis of COPD in patients with respiratory symptoms require detection of airflow obstruction ...

The US Food and Drug Administration (FDA) has approved mepolizumab as a maintenance treatment for chronic obstructive ...

Tezepelumab demonstrated clinically relevant benefits in specific inflammatory subtypes of COPD - an historically underserved market.

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as an add-on maintenance treatment for adult patients with inadequately ...

GSK’s Nucala receives US FDA approval for use in adults with chronic obstructive pulmonary disease: London, UK Saturday, May 24, 2025, 11:00 Hrs [IST] GSK plc announced that the ...

Incorporating chest CT imaging and respiratory symptoms into the chronic obstructive pulmonary disease (COPD) diagnostic ...

Dr Noor Zehan warned that regular vaping among teenagers could increase the risk of chronic bronchitis, early-onset chronic obstructive pulmonary disease (COPD), and persistent asthma — even after ...

Nucula’s new indication is as an add-on therapy for patients with COPD who also have an elevated blood eosinophil count.

When you are diagnosed with COPD, it is important to remember that you are not alone. A healthcare team, which may include a ...